Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K1-70 Single Ascending Dose IV Study in Graves' Disease
jRCT2080224902Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of K1-70 in Graves' disease (4 arms), sponsored by GSK. Primary endpoints: Safety and tolerability of single ascending IV doses of K1-70, Pharmacokinetics of K1-70 and 1 more. Started Oct 2019; status: completed.
02
Drugs
K1-70
03
Conditions
Graves' disease
Beyond the preview
Go deeper on jRCT2080224902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224902.